246
Views
0
CrossRef citations to date
0
Altmetric
Articles

Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis

, , , , , , , & ORCID Icon show all
Pages 19-27 | Received 23 Mar 2017, Accepted 17 Jan 2018, Published online: 01 Feb 2018
 

ABSTRACT

Conditionally replicative adenoviruses (CRAds) replicate poorly in murine cancer cells; however, E1b-deleted CRAds may replicate effectively in HPV16-E6/E7-positive murine cancer cells (TC-1). The HPV16 E7 open reading frame encodes functions analogous to these deleted adenovirus E1 proteins. In this study, an E1b-deleted CRAd (Adhz60) was evaluated for its ability to replicate and induce oncolysis in TC-1 cells. Adhz60-mediated oncolysis was similar in TC-1 and HeLa cells. Productive viral replication was evident based on expression of E1A and hexon, production of infectious virus progeny, and Adhz60-induced apoptosis. The results suggest that TC-1 murine cancer cells allow Adhz60 replication and oncolysis.

Acknowledgments

This study was supported in part by National Institutes of Health/NCI award R21CA210202 (J. G. G. G.). E.M.J. is recipient of a scholarship from the National Council of Science and Technology (CONACYT) of Mexico (award #296375). We thank Margaret Abby for editing this manuscript.

Declaration of interest

The authors report no potential conflict of interest. The authors alone are responsible for the content and writing of the paper.

Additional information

Funding

National Cancer Institute, R21CA210202.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.